Default company panoramic image

Accuitis Pharmaceuticals, Inc.

Accuitis is an early stage Bio-Tech start up focused on developing pharmaceuticals for under-served dermatological and ophthalmic diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Atlanta, GA, USA
  • Currency USD
  • Founded April 2011
  • Employees 4
  • Website

Company Summary

Accuitis has licensed technology from Emory University. Our lead compound (ACU-D1) is a first in class topical proteasome inhibitor which addresses inflammation and collagen-degradation. ACU-D1 is a potential therapy for Rosacea, Acne, Psoriasis and Skin Aging. We are initially seeking approval for Rosacea, a market opportunity > $1.5 Billion/year with very limited existing therapeutic options. Additional indications will follow thereafter.


  • Default avatar
    Rick Coulon
    President, CEO

    Rick has over 25 years of experience in pharmaceutical commercialization and business development. Experience includes: Managing Partner of C.C.G. Partners, a consulting business focused on commercialization, strategy, and business development for dermatology and ophthalmic pharmaceutical & medical device markets. SVP of Comm Ops at Auriga Labs; Positions at StoneBridge (Stiefel Labs/GSK); Akorn; Mallinckroft (Covidien) & CIBA Vision (Novartis).

  • Default avatar
    Jack L Arbiser, MD, Ph.D
    Chief Innovation Officer

    Jack is an internationally known thought leader in dermatology and oncology. In 1998, he established a laboratory at Emory University, where he is Full Professor. He currently serves on the editorial board of the Journal of Investigative Dermatology, and has served on the editorial board of the Journal of the American Academy of Dermatology and the Journal of Cutaneous Medicine and Surgery. He obtained an MD and PhD at Harvard Medical School.

  • Default avatar
    Michael G Shippel, CPA
    Chief Financial Officer

    Mike has diverse experience in the ophthalmic field, ranging from corporate finance & accounting to strategic planning, brand management and business development. He played a key financial role at Novartis in capital expenditure planning and product acquisitions & divestitures. He is the Co-Founder & President and of Creative Displays a company which designs and manufactures point of use storage systems for medical device and pharma companies.

  • Default avatar
    Thomas Rowe
    Chief Development Officer

    Tom has 24+ years Pharma experience with 20+ years in the Ophthalmics with Novartis. As VP of Quality & Technical Affairs he was responsible for global quality for ophthalmic products. He is currently the CEO/ President and Co-Founder of Encompass Pharmaceutical Services, which provides formulation development services in ophthalmic and dermatology drug development and analytical testing and stability services to the pharmaceutical industry.

  • Default avatar
    Steve Martin
    Board of Directors

    Steve has 34+ years experience in ophthalmic pharmaceuticals and medical devices. He is currently CEO of QSpex Technologies. He founded CIBA Vision in 1980 and CIBA Vision Ophthalmics (now Novartis Ophthalmics) in 1990. He grew sales of the combined companies to over $1.3 Billion annually with over 6,000 employees. Steve currently is a director of La Jolla Pharmaceuticals (LJPC: OTC BB), OcuCure Therapeutics, NeoVista & QSpex Technologies.

  • Default avatar
    Daniel White
    Board of Directors

    Mr. White is an experienced entrepreneur who is CEO of Clearside Biomedical, which is his 3rd Biotech startup. Mr. White has served in Sr. Corporate Development roles with GlaxoSmithKline, Stiefel, and CIBA Vision. He was a founding member of Alimera Sciences as VP of Finance and Corporate Development. He has participated in private equity raises and sales of assets of over $120 Million. He has helped commercialized 8 Ophthalmology products.

  • Default avatar
    Jason Thomas, JD
    Chief Legal Officer

    Jason currently serves as General Counsel of Total Dental, a privately owned dental software company based in Atlanta, Georgia. Prior to joining Total Dental, Jason was a SVP at Wells Fargo, The Private Bank. Prior to Wells Fargo he was a Tax Director at PricewaterhouseCoopers. Jason began his career as a Corporate Attorney with a concentration in the areas of general corporate, tax planning and litigation, and estate and planning.


  • Default avatar
    Frank McDaniel (Corporate) / Holquist LLP (IP)

Previous Investors

  • Default avatar
    Emory University - Office of Technology Transfer
    Default avatar
    Michael W. Padgett